TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock News

USA - NYSE:TAK - US8740602052 - ADR

14.01 USD

-0.05 (-0.36%)

Last: 10/24/2025, 8:04:00 PM

14 USD

-0.01 (-0.07%)

After Hours: 10/24/2025, 8:04:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TAK Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Innovent Biologics

News Image

Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market

3 days ago - By: Takeda Pharmaceutical Company Limited

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors

11 days ago - By: Benzinga

Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact

15 days ago - By: Benzinga - Mentions: JNJ PTGX

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report

a month ago - By: Takeda Pharmaceutical Company Limited

20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries

a month ago - By: The Motley Fool - Mentions: MO PFE XOM BTI

5 Best High-Yield Dividend Stocks to Buy Now

a month ago - By: Takeda Pharmaceutical Company Limited

Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran

5 months ago - By: Zacks Investment Research - Mentions: GRFS ADMA

ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?

6 months ago - By: Zacks Investment Research - Mentions: MFG LTM FIVN

Top 4 GARP Stocks With Attractive PEG Ratios to Watch

a month ago - By: Takeda Pharmaceutical Company Limited

Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit

2 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

2 months ago - By: Takeda Pharmaceutical Company Limited

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

2 months ago - By: Yahoo Finance

Takeda Pharmaceutical Company Limited (TAK) Advances γδ T Cell Cancer Treatments

3 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

3 months ago - By: Investor's Business Daily - Mentions: RY RY.CA ALKS CNTA ...

Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives.

3 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration

3 months ago - By: Yahoo Finance

Takeda Pharmaceutical (TAK) Gets GAMMAGARD LIQUID ERC Approved by FDA

3 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

4 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

4 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Announces New Assignments of Directors

5 months ago - By: Takeda Pharmaceutical Company Limited

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

5 months ago - By: Takeda Pharmaceutical Company Limited - Mentions: PTGX

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

5 months ago - By: Takeda Pharmaceutical Company Limited

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

5 months ago - By: Yahoo Finance - Mentions: MSFT VRT NVDA META ...

Build 2025 Highlights Microsoft (MSFT)’s Push Toward a Collaborative AI Future

5 months ago - By: Yahoo Finance - Mentions: NVDA VRT CMI MSFT ...

Vertiv Enhances AI Infrastructure with NVIDIA (NVDA) 800V DC

5 months ago - By: Takeda Pharmaceutical Company Limited

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

6 months ago - By: Yahoo Finance - Mentions: AAPL MSFT C

US and China to slash tariffs for 90 days as Trump and Xi likely to talk 'maybe at the end of the week'

6 months ago - By: Investor's Business Daily - Mentions: GILD PFE NVS ABBV ...

S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform

6 months ago - By: Zacks Investment Research - Mentions: GRFS ADMA

ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?